eligibility_summary
Eligible: adults ≥18 with biopsy‑proven CD20+ follicular lymphoma grade 1–3A, stage III/IV, measurable PET‑avid disease, exactly 1 prior chemoimmunotherapy line with PR/SD (not PD), completed ≥4 wks prior, ECOG ≤2, life expectancy >2 yrs, adequate marrow/organ function, controlled HBV/HCV, prior curable malignancy >2 yrs OK. Exclude: CNS involvement, major cardiac/neurologic disease, active infection, recent immunosuppression, pregnancy, HIV, live vaccine, prior investigational agents, allergy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2, single‑arm study of epcoritamab (DuoBody‑CD3xCD20, GEN3013), a humanized IgG1 bispecific T‑cell–engaging antibody given subcutaneously, in adults with CD20+ follicular lymphoma (grades 1–3A) who failed to achieve complete response after first‑line anti‑CD20 chemoimmunotherapy. Mechanism: co‑binding CD20 on malignant B cells and CD3 on T cells to create an immune synapse, activate T cells, and induce perforin/granzyme‑mediated cytotoxic killing of B cells, associated with cytokine release and downstream immune activation. Targets: CD20+ B‑cell lymphoma cells and CD3 on T‑lymphocytes, pathways include T‑cell activation signaling and B‑cell apoptosis. Up to 12 treatment cycles with imaging/marrow assessments, goal is second‑line efficacy.